DILIsym releases new version of NAFLD treatment development software

DILIsym Services released NAFLDsym Version 2A, a quantitative systems pharmacology modeling software designed to support the development of treatments for nonalcoholic fatty liver disease, according to a press release.

“We are excited about the release of NAFLDsym v2A, as we believe it will assist the pharmaceutical industry by bringing effective medications to nonalcoholic steatohepatitis (NASH) patients in a timely and cost-efficient manner,” Scott Q. Siler, PhD, chief scientific officer of DILIsym Services, said in the release.

“The quantitative systems modeling introduced with NAFLDsym v2A enables users to evaluate key pathophysiologic areas of evaluation in NASH drug development, such as how drug candidates affect steatosis, lipotoxicity, inflammation, and fibrosis,” Siler continued. “In particular, NAFLDsym v2A allows users to predict efficacy in NASH patients for combinations of treatments, which is thought to be the best path for treating this disease.”

Features of the software include more than 1,000 simulated patients with variability in pathophysiology along with scores that allow users to test simulated patient cohorts, clinical biomarkers such as MRI measurements, test strategies to prevent or reverse fibrosis and steatosis, test strategies to prevent lipotoxicity and inflammation, and measurements of weight gain or loss related to disease progression.

“NAFLDsym v2A is the result of an immense effort by our highly skilled modeling and simulation team and the support of our corporate sponsor,” Shawn O’Connor, CEO of parent company Simulations Plus, said in the release. “We look forward to the continuing use of predictive modeling and simulation tools to reduce the cost and improve the efficiency of drug development.”

Reference: www.dilisymservices.com